J. A. Valderrama, J. A. Ibacache / Tetrahedron Letters 50 (2009) 4361–4363
4363
ridinequinone derivatives. The effect of remote substituents and
the catalysis on the control of the regioselectivity of the studied
reaction, together with the significant anticancer activity observed
on the 8-regioisomers, appears as valuable precedents toward the
development of new aminophenanthridinequinone-containing
antitumor drugs. The scope of the amination reaction on phenanth-
ridinequinone directed to prepare a variety of new members of this
class of N-heterocyclic quinones, and their biological evaluation on
representative cancer cell lines, are in progress in our laboratory.
Acknowledgment
We thank the FONDECYT and CONICYT (Grants No. 1060591;
AT-24080014) for financial support of this study.
References and notes
1. Pettit, G. R.; Knight, J. C.; Collins, J. C.; Herald, D. L.; Pettit, R. K. J. Nat. Prod. 2000,
63, 793–798.
Figure 1. Minimized molecular model of quinone 7.
2. Rao, K. V.; Beach, J. W. J. Med. Chem. 1991, 34, 1871–1879.
3. Ryu, C.-K.; Lee, I.-K.; Jung, S.-H.; Kang, H.-Y.; Lee, C.-O. Med. Chem. Res. 2000, 10,
40–49.
4. Chung, K.-H.; Hong, S.-Y.; You, H.-J.; Park, R.-E.; Ryu, C.-K. Bioorg. Med. Chem.
2006, 14, 5795–5801.
5. Sarma, M. D.; Ghosh, R.; Patra, A.; Hazra, B. Eur. J. Med. Chem. 2008, 43, 1878–1888.
6. Ling, R.; Yoshida, M.; Mariano, P. S. J. Org. Chem. 1996, 61, 4439–4449.
7. Valderrama, J. A.; Ibacache, J. A.; Rodríguez, J. A.; Theoduloz, C. G. Bioorg. Med.
Chem. 2009, 17, 2894–2901.
8. Valderrama, J. A.; Colonelli, P.; Vásquez, D.; González, M. F.; Rodríguez, J.;
Theoduloz, C. Bioorg. Med. Chem. 2008, 16, 10172–10181.
9. Valderrama, J. A.; Colonelli, P.; Vásquez, D.; González, M. F. Synlett 2006, 2777–
2780.
nucleophile at the 8-position, which is in accordance with the the-
oretical predictions.13
Since the electron-withdrawing effect of the heterocyclic nitro-
gen atom in dienophile 7 does not have a significant influence on
the regioselectivity of the substitution reaction apparently, the
control could be determined in part by steric interactions between
the C-1 and C-10 carbonyl groups into the dienophile.
An inspection of the molecular model of 7 (Fig. 1) shows an
inhibition to the coplanarity of the C-10 carbonyl group with re-
spect to the quinone double bond, due to its steric interaction with
the carbonyl groups at C-1. This effect probably influences the elec-
tron-withdrawing ability of the C-10 carbonyl group so the prefer-
ential attack of the nucleophiles occurs at b-position to the C-7
carbonyl group.
10. Compound 9a: purple solid, mp 182–184 °C; IR (KBr): mmax 3447 (N–H), 1703
(C@O), 1607 and 1590 (C@O quinone); 1H NMR (CDCl3, 400 MHz): d 2.22 (t,
J = 6.5 Hz, 2H, 3-H), 2.89 (t, J = 6.5 Hz, 2H, 2-H), 3.18 (t, J = 6.5 Hz, 2H, 4-H), 6.31
(s, 1H, 8-H), 7.23 (m, 3H, arom.), 7.25 (m, 2H, arom.), 7.41 (s, 1H, NH), 9.33 (s,
1H, 6-H); 13C NMR (CDCl3, 100 MHz): d 21.50, 33.39, 39.26, 102.24, 122.67,
124.25 (2C), 126.25, 128.89 (2C), 129.83,136.93, 140.44, 143.75, 150.75,
3
167.65, 180.79, 181.97, 197.62. The HMBC spectrum of 9b shows JC,H
The regioselectivity of the substitution reaction on quinone 8
can be explained assuming steric and electron-donor interactions
between the methyl and C-7 carbonyl groups. These factors prob-
ably affect the electrophilicity of the C-9 atom and the attack of the
nucleophiles occurs at b-position to the C-10 carbonyl group.
With regard to the experiments on the reactions of quinone 7
with the nucleophiles performed with CeCl3ꢀ7H2O catalyst, a rever-
sal of the regioselectivity with respect to the uncatalyzed reaction
is induced. However, in quinone 8 the catalyst does not change the
regioselectivity of the substitution at the 8-position, as in the case
of the uncatalyzed reactions.
The effect of the catalyst to promote the attack of the nucleophile
at the 8-position in both quinones may be ascribed to coordination
of the cerium ion to the heterocyclic nitrogen atom and/or the car-
bonyl group at the C-10 position. The coordination strongly en-
hances the electron-withdrawing capacity of the carbonyl group at
the C-10 position, which is transferred to the 8-position, leading to
preferential C-8 substitution via nucleophilic attack by the amines.
Some members of the aminophenanthridinequinone deriva-
tives were evaluated in vitro against human gastric adenocarci-
noma and lung cancer cell lines to get preliminary information
on their cytotoxic activities. The screening showed that com-
pounds 9a, 9b, 12a, and 12b exhibit significant antitumor activity
coupling of the C-10 carbon (d 180.79 ppm) with the protons at: d 7.41 and
6.31.HRMS (M+): m/z calcd for C19H14N2O3 [M+]: 318.10044; found:
318.10005.
11. Compound 9b: red solid, mp 179–182 °C; IR (KBr): mmax 3441 (N-H),1668
(C@O),1610 and 1566 (C@O quinone); 1H NMR (CDCl3, 400 MHz): d 2.21 (t,
J = 6.5 Hz, 2H, 3-H), 2.89 (t, J = 6.5 Hz, 2H, 2-H), 3.13 (t, J = 6.5 Hz, 2H, 4-H), 6.43
(s, 1H, 9-H), 7.23 (m, 3H, arom.), 7.25 (m, 2H, arom.), 7.41 (s, 1H, NH), 9.24 (s,
1H, 6-H); 13C NMR (CDCl3, 100 MHz): d 21.37, 33.40, 39.13, 104.99, 122.67,
124.25 (2C), 126.09, 128.90 (2C), 129.84, 136.92, 140.45, 143.74, 149.66,
169.79, 180.80, 181.42, 198.00. The HMBC spectrum of 9a shows 3JC,H coupling
of the C-7 carbon (d 181.42 ppm) with the protons at: d 9.24; 7.41 and
6.43 ppm.HRMS (M+): m/z calcd for C19H14N2O3: 318.10044; found: 318.10012.
12. Compound 13: dark red solid, mp 180–183 °C; IR (KBr): mmax 3443 (N-H), 1696
(C@O), 1591 and 1564 (C@O quinone), 1H NMR (CDCl3, 400 MHz): d 2.20 (t,
J = 6.7 Hz, 2H, 3-H), 2.85 (t, J = 6.7 Hz, 2H, 2-H), 2.92 (s, 3H, 6-CH3), 3.05 (t,
J = 6.7 Hz, 2H, 4-H), 6.35 (s, 1H, 9-H), 7.22 (m, 3H, arom.), 7.38 (m, 2H, arom.),
7.74 (s, 1H, NH); 13C NMR (CDCl3, 100 MHz): d 21.39, 26.33, 33.18, 39.12,
103.27, 122.58 (2C), 125.82, 128.07, 129.71 (2C), 137.17, 143.43, 144.74,
146.54, 162.27, 167.64, 181.42, 181.99, 198.64. The HMBC spectrum of 13
3
shows JC,H coupling of the C-7 carbon (d 181.99 ppm) with the protons at d
4
7.74 and 6.35 ppm, and JC,H coupling of the C-7 carbon (d 181.99 ppm) with
the protons of the methyl group at d 2.92 ppm.HRMS (M+): m/z calcd for
C19H14N2O3 [M+]: 332.11609; found: 332.11552.
13. The LUMO eigenvector coefficients were obtained with DFT level in B3LYP/6-
31G using the package GAUSSIAN 03. Compound 7: C8 = ꢁ0.20625,
C9 = 0.19330 eV. Compound 8: C8 = ꢁ0.20483, C9 = 0.19584 eV.
14. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.;
Cheeseman, J. R.; Montgomery, Jr., J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.;
Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.;
Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.;
Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao,
O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken,
V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A.
J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G.
A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.;
Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.;
Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.;
Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.;
Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe,
M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; and Pople,
J. A. GAUSSIAN 03, Revision C.02; Gaussian: Wallingford, CT, 2004.
in the range IC50: 0.23–7.5
9b and 12b exhibit higher antitumor activity (IC50 = 0.23 and
0.38 M) than their corresponding regioisomers 9a and 12a
(IC50 = 3.9 and 2.3 M) on gastric cancer cells. The antitumor activ-
ity of compounds 9b and 12b on gastric cancer cells was compara-
ble to that shown by the reference drug etoposide (IC50 = 0.36 M).
lM. It is noteworthy that compounds
l
l
l
In conclusion, we have described the reaction of two
representative phenanthridinequinones with amines that provides
a regioselective access to potentially antitumor aminophenanth-